MX2025012580A - Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal - Google Patents

Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal

Info

Publication number
MX2025012580A
MX2025012580A MX2025012580A MX2025012580A MX2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A MX 2025012580 A MX2025012580 A MX 2025012580A
Authority
MX
Mexico
Prior art keywords
von willebrand
patients
administration
treatment
gastrointestinal bleeding
Prior art date
Application number
MX2025012580A
Other languages
English (en)
Spanish (es)
Inventor
Miranda Chapman
Bruce Ewenstein
Bettina Ploder
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2025012580A publication Critical patent/MX2025012580A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2025012580A 2017-07-07 2020-01-08 Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal MX2025012580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Publications (1)

Publication Number Publication Date
MX2025012580A true MX2025012580A (es) 2026-01-07

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025012580A MX2025012580A (es) 2017-07-07 2020-01-08 Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal

Country Status (16)

Country Link
US (5) US10632176B2 (https=)
EP (2) EP3648788B1 (https=)
JP (2) JP7307047B2 (https=)
KR (2) KR20260037107A (https=)
CN (1) CN111436193A (https=)
AU (2) AU2018298233B2 (https=)
BR (1) BR112020000321A2 (https=)
CA (1) CA3069295A1 (https=)
CO (1) CO2020001322A2 (https=)
DK (1) DK3648788T3 (https=)
ES (1) ES2986574T3 (https=)
FI (1) FI3648788T5 (https=)
MX (1) MX2025012580A (https=)
PL (1) PL3648788T3 (https=)
PT (1) PT3648788T (https=)
WO (1) WO2019010497A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
US12128090B2 (en) * 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
EP4013389A1 (en) * 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CA2591852A1 (en) 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
ES2392569T3 (es) 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010279463A1 (en) 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
CA2805557A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant high molecular weight vwf in cell culture
ES2682249T3 (es) * 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf

Also Published As

Publication number Publication date
JP2023123738A (ja) 2023-09-05
US12016904B2 (en) 2024-06-25
RU2020105682A3 (https=) 2021-10-15
US10632176B2 (en) 2020-04-28
CO2020001322A2 (es) 2020-02-18
AU2018298233B2 (en) 2025-04-24
RU2020105682A (ru) 2021-08-10
KR20260037107A (ko) 2026-03-17
WO2019010497A1 (en) 2019-01-10
US20230122958A1 (en) 2023-04-20
AU2025205392A1 (en) 2025-09-25
JP7641327B2 (ja) 2025-03-06
US11529395B2 (en) 2022-12-20
PL3648788T3 (pl) 2024-10-07
BR112020000321A2 (pt) 2020-07-14
CA3069295A1 (en) 2019-01-10
EP3648788A1 (en) 2020-05-13
PT3648788T (pt) 2024-08-23
US20240316160A1 (en) 2024-09-26
EP4424366A3 (en) 2024-12-04
US20200206318A1 (en) 2020-07-02
JP7307047B2 (ja) 2023-07-11
JP2020526525A (ja) 2020-08-31
US20210169989A1 (en) 2021-06-10
US10905746B2 (en) 2021-02-02
US20190091299A1 (en) 2019-03-28
CN111436193A (zh) 2020-07-21
KR20200037235A (ko) 2020-04-08
AU2018298233A1 (en) 2020-01-30
FI3648788T5 (fi) 2024-09-09
EP4424366A2 (en) 2024-09-04
DK3648788T3 (da) 2024-08-19
FI3648788T3 (fi) 2024-08-16
EP3648788B1 (en) 2024-05-22
ES2986574T3 (es) 2024-11-12
KR102921337B1 (ko) 2026-02-02

Similar Documents

Publication Publication Date Title
MX2025012580A (es) Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal
CL2022002836A1 (es) Polipeptidos derivados de cancer (divisional 201902533)
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
JP2014516088A5 (https=)
FI3261661T3 (fi) Menotropiini hedelmättömyyden hoitamiseksi
RU2017128296A (ru) Композиция для лечения бесплодия
MY204827A (en) Semaglutide in medical therapy
EP4621067A3 (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2022005664A (es) Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer.
MX2018000240A (es) Metodos para tratar el vhc.
PH12015502100A1 (en) Reducing the risk of autoimmune disease
MX2024004333A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante
JP2014530246A5 (https=)
EA202192140A1 (ru) СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
EA201291384A1 (ru) Терапевтические агенты 976
MX2022009492A (es) Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.
RU2022116119A (ru) Лечение желудочно-кишечного кровотечения у пациентов с тяжелой формой болезни фон виллебранда путем введения рекомбинантного ффв
AR118608A2 (es) TRATAMIENTO DE LOS TRASTORNOS DE LA COAGULACIÓN MEDIANTE LA ADMINISTRACIÓN DE UN FACTOR DE VON WILLEBRAND (vWF) RECOMBINANTE
RU2015147544A (ru) Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе
Bravo et al. VWF modulates the in vivo FVIII recovery of different FVIII concentrates in a mice model of severe hemophilia with inhibitors